JG
CLDX icon

Jefferies Group’s Celldex Therapeutics CLDX Stock Holding History

Jefferies Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$450K Sell
16,000
-107,500
-87% -$3.3M ﹤0.01% 1068
2022
Q2 		$3.33M Buy
123,500
+107,500
+672% +$3.12M 0.03% 458
2022
Q1 		$545K Sell
16,000
-24,000
-60% -$767K ﹤0.01% 1034
2021
Q4 		$1.55M Buy
40,000
+16,000
+67% +$697K 0.01% 875
2021
Q3 		$1.3M Buy
+24,000
New +$1.13M 0.01% 900
2021
Q2 		– Sell
-107,000
Closed -$2.2M – 1712
2021
Q1 		$2.2M Buy
+107,000
New +$2.46M 0.02% 646
2014
Q2 		– Sell
-1,833
Closed -$486K – 2105
2014
Q1 		$486K Buy
+1,833
New +$702K ﹤0.01% 1284

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jefferies Group's CLDX Position: Q3 2022 in Review

Jefferies Group sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 59,098 shares — an estimated $1.81M sold.

Jefferies Group first reported a position in CLDX in Q2 2013 and held it in 10 quarters. The position peaked at $1.59M in Q2 2022. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Jefferies Group reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 59,098 Celldex Therapeutics shares in Q3 2022, an estimated $1.81M.
  • Jefferies Group first reported a position in Celldex Therapeutics in Q2 2013 and held it in 10 quarters.
  • Jefferies Group's Celldex Therapeutics position peaked at $1.59M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.